Skip to content
Triveni Bio
News

The latest company updates, news, and insights

Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples

Press Release
9.23.2025

Fierce Biotech names Triveni Bio a “Fierce 15” Biotech Company of 2025

Press Release
9.22.2025

Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis

Press Release
5.21.2025

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders

Press Release
10.2.2024

Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer, Announces Key Program Updates

Press Release
6.12.2024

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors

Press Release
12.13.2023

Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders

Press Release
10.26.2023
Top